Medtronic (NYSE: MDT) today announced study results backing its adaptive DBS algorithm for personalized therapy in Parkinson's.
Discover Summit Luxeron - an AI-powered trading platform built on transparency, security, and smart algorithms for traders of all levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback